Why Patients Ask Which Conditions MUSE Cells Therapy Treats
If you have searched MUSE cells therapy, you have probably seen long lists of conditions. Few of them have published human results. This guide sorts conditions by the strength of evidence, so you can see where your own diagnosis fits.
New to the topic? Start with what MUSE cells are and how they differ from MSCs.
MUSE Cells Therapy Conditions by Evidence Level
| Condition | Evidence stage | Read more |
|---|---|---|
| Subacute ischaemic stroke | Small placebo-controlled human trial | MUSE cells after stroke |
| Acute heart attack | First-in-human study in 3 patients | MUSE cells and heart attack |
| Dystrophic epidermolysis bullosa | Small open-label human study | MUSE cells and EB |
| Liver fibrosis and cirrhosis | Animal studies only | MUSE cells and cirrhosis |
| Tinnitus and hearing | No published human MUSE result found | MUSE cells and tinnitus |
What Human MUSE Cells Therapy Studies Show
Niizuma and colleagues reported a randomised placebo-controlled trial of CL2020 in subacute ischaemic stroke. Noda and colleagues reported a first-in-human study in three heart attack patients. Fujita and colleagues reported a phase 1/2 open-label study in adults with dystrophic epidermolysis bullosa.
These studies were designed mainly to check safety and early signals. They are too small to establish effectiveness. See MUSE cell safety evidence.
MUSE Cell Therapy Approach Across Conditions
- How it works: MUSE cells are proposed to sense injury signals, travel to damaged tissue and support repair.
- Who may be suitable: no routine candidate group exists. Suitability depends on the condition, its stage and available evidence.
- What a session involves: the human studies used intravenous infusion. See what a MUSE stem cell treatment visit involves.
- Limits: early-phase or animal evidence only. No condition has a proven MUSE cure.
Depending on the condition, other regenerative options such as MSC therapy may be discussed as options. Visit our MUSE cell therapy service page.
How to Check MUSE Cells Therapy Claims for Your Condition
- Is there a published human study for this exact condition?
- How many people were studied, and was there a comparison group?
- Was the same cell product used as the one offered?
- What established care should continue alongside?
Comparing technologies? Read MUSE cells vs iPS cells.
For kidney concerns, read MUSE cell therapy and chronic kidney disease.
Next Steps After Reviewing MUSE Cells Therapy Evidence
If you are considering travel, our guide to planning MUSE cell therapy in Thailand lists the questions to ask a provider. Interested in longevity rather than one diagnosis? Read MUSE cell therapy for healthy aging.
Bottom line: MUSE cells therapy has early human data in stroke, heart attack and epidermolysis bullosa, and animal data elsewhere. It remains investigational for every condition.
Medical References
- Niizuma K and colleagues, 2023. Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke
- Noda T and colleagues, 2020. Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial
- Fujita Y and colleagues, 2021. Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open-label study
- Iseki M and colleagues, 2017. Muse Cells, Nontumorigenic Pluripotent-Like Stem Cells, Have Liver Regeneration Capacity Through Specific Homing and Cell Replacement in a Mouse Model of Liver Fibrosis
Talk to a Doctor Before You Decide
Tell us your diagnosis and share your records. Our team can explain where MUSE cells therapy evidence stands for your condition and which established options come first.
Schedule a Consultation





